Researchers identified critical educational gaps that need to be addressed by manufacturers and policymakers in order for biosimilars to achieve their potential for lowering the cost of cancer care in the United States.
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.
Systemic therapy for bladder cancer is costly and should be weighed against the clinical outcomes likely to be achieved.
This retrospective, longitudinal study was conducted to identify drivers of chronic kidney disease stage progression and associated health care costs.
The potential impact of CAR-T therapies should not be underestimated, nor should their complexity, which is why a broader understanding of stakeholder knowledge and perception may be critical to their adoption and use.
The Impact of Decreasing Variability in Surgical Care Through a Structured Multi-Disciplinary Thoracic Oncology Program
Post-TOP lobectomy is associated with increased clinical staging, greater utilization of mediastinoscopy and bronchoscopy, performance of minimally invasive resection, greater number of lymph nodes procured, and decreased length of stay.
The Impact of a Multidisciplinary Care Coordination Protocol On Patient-Centered Outcomes at an Academic Medical Center
Implementation of a standardized multidisciplinary rounds protocol can improve care coordination, patient assessments of care quality, and patient length of stay.
Researchers show that patient navigation programs can reduce provider costs by decreasing missed colorectal cancer screening appointments.
Length of Stay and Costs of COPD: Analysis of Hospitalized Patients Treated With Arformoterol or Nebulized Short-Acting Beta2-Agonists
COPD patients treated with nebulized arformoterol experienced shorter LOS and reduced total hospitalization costs compared with nebulized SABA–treated patients.
The adoption of clinical pathways is standardizing the cancer care process, with adherence to established protocols impacting efficacy, safety, and cost of care.